Nonopioid Analgesia After Rotator Cuff Repair
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03818919 |
|
Recruitment Status :
Recruiting
First Posted : January 28, 2019
Last Update Posted : January 28, 2019
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Rotator Cuff Tear | Drug: Celecoxib Drug: Ketorolac Drug: Gabapentin Drug: Acetaminophen Drug: Diazepam Drug: Hydrocodone-Acetaminophen | Phase 2 |
Study Design: This is a randomized, single blinded, standard of care-controlled clinical trial. All adult patients over eighteen desiring rotator cuff repair will be eligible. Nonnarcotic postoperative pain control regimen described below were chosen based on previous studies in fracture care and joint arthroplasty.
Patients will be consented and recruited. Once participation has been determined and consent obtained, the names of participating patients will be provided to the research pharmacy. Patients will be randomized with a computer-generated table in 2 patient blocks by the research pharmacy. Patients postoperative analgesia will be divided into one of the following 2 treatment arms: 1) A novel nonopioid pain protocol or 2) traditional narcotic pain analgesia
Primary endpoints is reduction in pain as measured by visual analogue scale and Patient-Reported Outcomes Measurement Information System. The endpoints will be collected at each post-operative day using a journal. Moreover, endpoints will be collected at the patient's first post-operative appointment. These appointments are scheduled within one-week of the index procedure.
Statistical Analysis: All continuous data will be analyzed using independent 2-group t tests and reported as means ± standard deviations. Categorical data will be compared between the 2 groups using chi-square tests and reported as counts and percentages. A preliminary test to confirm the quality of variances will be conducted prior to utilizing the t test to confirm the appropriate statistical analysis. Nonparametric equivalents Wilcoxon rank-sum and Fisher exact tests will be used as needed for nonnormal distributions and low variable numbers, respectively. A multivariable regression analysis was performed to assess for potential confounding demographic variables.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 100 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Care Provider) |
| Primary Purpose: | Treatment |
| Official Title: | Traditional vs. Nonopioid Analgesia After Rotator Cuff Repair |
| Actual Study Start Date : | January 22, 2019 |
| Estimated Primary Completion Date : | January 20, 2020 |
| Estimated Study Completion Date : | May 20, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Post-Operative Non Opioid Pain Protocol
Patients in this group will be administered a novel multimodal pain protocol post-operatively consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
|
Drug: Celecoxib
Post-Operative Non Opioid Pain Protocol
Other Name: Celebrex Drug: Ketorolac Post-Operative Non Opioid Pain Protocol
Other Name: Tylenol Drug: Gabapentin Post-Operative Non Opioid Pain Protocol
Other Name: Neurontin Drug: Acetaminophen Post-Operative Non Opioid Pain Protocol
Other Name: Tylenol Drug: Diazepam Post-Operative Non Opioid Pain Protocol
Other Name: Valium |
|
Active Comparator: Post-Operative Traditional Pain Protocol
Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-Acetaminophen Cap 5-500
|
Drug: Hydrocodone-Acetaminophen
Traditionally used narcotic pain protocol
Other Name: Norco |
- Pain Levels [ Time Frame: 10 days post-operatively ]Patients record pain levels every 3 hours using Visual analog scales for 10 days post-operatively. Average daily pain was calculated for each patient. Higher values portend worse control.
- Patient-Reported Outcomes Measurement Information System [ Time Frame: 10 days post-operatively ]Patient-Reported Outcomes Measurement Information System Physical Interference (PROMIS PI) once every night for 10 days post-operatively. Average PROMIS PI values calculated nightly. A higher score indicates more pain interference.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- All adult patients over age 18 and scheduled for a primary or revision rotator cuff repair
Exclusion Criteria:
- Exclusion criteria will include patients with a medical history of known allergies or intolerance to allergies or intolerance to Celebrex, Tylenol, Neurontin, dexamethasone, tramadol, substantial alcohol or drug abuse, and pregnancy, history of narcotics within 6 months of surgery, renal impairment, peptic ulcer disease, GI bleeding. Secondary exclusion criterion is an intact rotator cuff
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03818919
| Contact: Toufic R Jildeh, MD | 5172308511 | tjildeh1@hfhs.org |
| United States, Michigan | |
| Health Ford Health System | Recruiting |
| Detroit, Michigan, United States, 48202 | |
| Contact: Toufic R Jildeh, MD | |
| Principal Investigator: | Toufic R Jildeh, MD | Resident |
| Responsible Party: | Toufic R. Jildeh, Resident, Henry Ford Health System |
| ClinicalTrials.gov Identifier: | NCT03818919 |
| Other Study ID Numbers: |
123191 |
| First Posted: | January 28, 2019 Key Record Dates |
| Last Update Posted: | January 28, 2019 |
| Last Verified: | January 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Plan Description: | Per Request |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | Yes |
|
Rotator Cuff Injuries Rupture Wounds and Injuries Shoulder Injuries Tendon Injuries Acetaminophen Celecoxib Ketorolac Acetaminophen, hydrocodone drug combination Diazepam Gabapentin Hydrocodone Analgesics, Non-Narcotic Analgesics Sensory System Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Antipyretics Anti-Inflammatory Agents, Non-Steroidal Anti-Inflammatory Agents Antirheumatic Agents Cyclooxygenase 2 Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anticonvulsants Anti-Anxiety Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs |

